Why is Astrazeneca Phar falling/rising?

As of 04-Aug, Astrazeneca Pharma India Ltd is experiencing a price increase, currently at 8,979.95, reflecting a rise of 86.45 (0.97%). The stock has shown a trend reversal, gaining after two consecutive days of decline. Despite a decrease in delivery volume by 25.07% against the 5-day average, the stock outperformed its sector by 0.63% today. Over the past week, Astrazeneca has returned +0.59%, which is better than the Sensex's +0.16%. Year-to-date, the stock has delivered a robust return of +22.43%, significantly outperforming the Sensex's +3.69%. The company has demonstrated high management efficiency with a return on equity (ROE) of 19.06% and has maintained a low debt-to-equity ratio, which supports its positive performance.
In the broader market context, Astrazeneca's recent performance contrasts favorably with the benchmark, particularly in the short term, where it has outperformed the Sensex. However, there are concerns regarding its long-term growth potential, as operating profit growth has been modest at an annual rate of 15.95% over the last five years. The stock is considered expensive with a price-to-book value of 29.1, which is above its peers' average historical valuations. Despite these risks, the company has consistently generated positive returns over the last three years and has declared strong quarterly results, contributing to the stock's upward movement.